Latest news

• Myovant has second phase 3 trial to back its uterine fibroids drug

  and was due to be filed for the uterine fibroids indication right about now, giving it a few months’ head start. ... Analysts suggest that uterine fibroids could be a $1bn-plus market for GnRH antagonists.

• Myovant’s fibroids drug clears phase 3 trial, but shares sink

  Uterine fibroids are non-cancerous tumours that form in the muscle walls of the uterus and affect between 20% and 80% of women by the age of 50. ... Their drug is already approved as Orilissa to treat endometriosis and has two positive phase 3 readouts

• Urovant slips on phase 3 incontinence drug data

  Others cued up for results include phase 3 trials of Myovant’s relugolix in uterine fibroids, endometriosis and prostate cancer, and Dermavant’s tapinarof in psoriasis.

• AbbVie preps uterine fibroid filing after phase 3 win

  life. AbbVie says it is now planning to file its first applications for the drug in uterine fibroids in mid-2019. ... Uterine fibroids are non-cancerous tumours that form in the muscle walls of the uterus and affect between 20% and 80% of women by the

• FDA rejects Allergan’s uterine fibroid drug over safety concerns

  Allergan’s hopes of its investigational uterine fibroid drug hitting blockbuster status have taken a knock-back following a rejection on its marketing application by the US Food and Drug Administration ... He added: “Allergan continues to believe in